Figure 1.

Proportion of patients achieving (A) IBDQ remission (IBDQ ≥ 170) and (B) IBDQ response (IBDQ total score increase from baseline ≥16) at Week 12 and Week 52 in ELEVATE UC 52 and Week 12 in ELEVATE UC 12. Data labels present percentage value with n/N in brackets underneath. Difference from placebo is adjusted difference. 95% CI and 2-sided P-value are based on Cochran-Mantel-Haenszel method adjusting to reported randomization stratification of (1) naive-to-biologic or JAKi therapy at study entry, (2) baseline corticosteroid use, or (3) baseline disease activity (MMS 4-6 or 7-9). Abbreviations: Δ, difference from placebo; IBDQ, Inflammatory Bowel Disease Questionnaire; JAKi, Janus kinase inhibitor; MMS, modified Mayo score; n, number of patients; N, number of patients in the full analysis set; QD, once daily; UC, ulcerative colitis.